Constantiam Biosciences

Constantiam Biosciences is a private precision medicine and functional genomics company developing platform technologies to improve genetic variant interpretation and accelerate rare-disease and oncology drug discovery. The company combines multiplexed assays of variant effect, probabilistic or Bayesian machine learning, and human genetic data to generate functional evidence for variants and identify patient-responsive therapeutic opportunities. Its platform suite includes Varify for large-scale variant reclassification, MAVEvidence for evidence presentation and reporting, and RareScan for discovery and patient stratification. Constantiam is also advancing an internal therapeutics pipeline, including a lead small-molecule program for neuronopathic Gaucher disease developed through a collaboration with Cincinnati Children's. The company appears to operate as a preclinical-stage biotech with both platform and therapeutics ambitions.